X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PANACEA BIOTECH VENUS REMEDIES/
PANACEA BIOTECH
 
P/E (TTM) x -821.4 80.0 - View Chart
P/BV x 0.2 1.8 13.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PANACEA BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
PANACEA BIOTECH
Mar-14
VENUS REMEDIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs218149 146.6%   
Low Rs8282 99.8%   
Sales per share (Unadj.) Rs365.684.1 434.5%  
Earnings per share (Unadj.) Rs1.5-18.3 -8.1%  
Cash flow per share (Unadj.) Rs37.9-6.7 -566.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.583.7 457.0%  
Shares outstanding (eoy) m11.4461.25 18.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.4 29.9%   
Avg P/E ratio x101.0-6.3 -1,600.5%  
P/CF ratio (eoy) x4.0-17.2 -23.0%  
Price / Book Value ratio x0.41.4 28.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7177,074 24.3%   
No. of employees `0001.02.8 37.1%   
Total wages/salary Rs m3241,449 22.4%   
Avg. sales/employee Rs Th4,100.71,874.1 218.8%   
Avg. wages/employee Rs Th318.0527.0 60.4%   
Avg. net profit/employee Rs Th16.7-407.7 -4.1%   
INCOME DATA
Net Sales Rs m4,1835,154 81.2%  
Other income Rs m20100 20.1%   
Total revenues Rs m4,2035,254 80.0%   
Gross profit Rs m812-766 -105.9%  
Depreciation Rs m417711 58.6%   
Interest Rs m3801,503 25.3%   
Profit before tax Rs m35-2,881 -1.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1817 107.7%   
Profit after tax Rs m17-1,121 -1.5%  
Gross profit margin %19.4-14.9 -130.5%  
Effective tax rate %51.6-0.6 -8,841.6%   
Net profit margin %0.4-21.8 -1.9%  
BALANCE SHEET DATA
Current assets Rs m2,7713,810 72.7%   
Current liabilities Rs m1,9318,365 23.1%   
Net working cap to sales %20.1-88.4 -22.7%  
Current ratio x1.40.5 315.0%  
Inventory Days Days125156 80.3%  
Debtors Days Days5467 79.9%  
Net fixed assets Rs m5,32814,480 36.8%   
Share capital Rs m11461 186.6%   
"Free" reserves Rs m4,177903 462.5%   
Net worth Rs m4,3765,127 85.4%   
Long term debt Rs m1,9115,832 32.8%   
Total assets Rs m8,42819,433 43.4%  
Interest coverage x1.1-0.9 -119.2%   
Debt to equity ratio x0.41.1 38.4%  
Sales to assets ratio x0.50.3 187.1%   
Return on assets %4.72.0 239.7%  
Return on equity %0.4-21.9 -1.8%  
Return on capital %6.63.6 181.5%  
Exports to sales %024.5 0.0%   
Imports to sales %20.510.2 201.5%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs m858525 163.6%   
Fx inflow Rs m01,539 0.0%   
Fx outflow Rs m858942 91.1%   
Net fx Rs m-858597 -143.7%   
CASH FLOW
From Operations Rs m469599 78.2%  
From Investments Rs m29-438 -6.7%  
From Financial Activity Rs m-464-303 153.2%  
Net Cashflow Rs m35-141 -24.4%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 30.0%  
FIIs % 0.6 1.3 44.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.6 281.4%  
Shareholders   20,121 10,259 196.1%  
Pledged promoter(s) holding % 36.4 35.1 103.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   MERCK LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 23, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - PLETHICO PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS